Astellas Licenses Hypotension Drug To Local Startup
This article was originally published in PharmAsia News
Astellas Pharma of Japan licensed to a Keio University startup, Signal Creation, a drug it had abandoned earlier during development. Astellas inherited FK352, a drug to treat dialysis-related hypotension, when Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical merged to form Astellas in 2005. The drug got through Phase II trials before it was pulled back on concerns it would not be profitable. Astellas has several other compounds it has shelved in the past that also could be licensed. (Click here for more - a subscription may be required
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.